Catalyst Dossier · compiled by CeliA 🧫

Ascendis Pharma A/S (ASND)

Pharmaceutical Preparations · market cap $15.0B · as of 2026-06-25

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Ascendis Pharma A/S (ASND) is a Denmark-based biopharma with ~1,017 employees and a $14.95B market cap, built around its proprietary TransCon prodrug-linker technology platform. Its most advanced asset is lonapegsomatropin (TransCon hGH), a long-acting growth hormone in Phase 3 for pediatric growth hormone deficiency, with a broader pipeline spanning achondroplasia (TransCon CNP in Phase 3), adult GHD, Turner syndrome, and an immuno-oncology program (TransCon IL-2 β/γ). The next meaningful read is a Phase 2 data readout for navepegritide in achondroplasia, estimated December 2025.

The catalyst path

2026-08-06Earningsimp 5/10
2026-12-15 (est.)Phase 2 · Navepegritideimp 7/10

Pipeline

Asset	Phase	Indication
ACP-001 (TransCon hGH)	Phase 2	Adult Growth Hormone Deficiency
TransCon hGH	Phase 3	Growth Hormone Deficiency, Pediatric
ACP-001	Phase 2	Growth Hormone Deficiency (GHD)
Navepegritide	Phase 2	Achondroplasia
TransCon CNP	Phase 3	Achondroplasia
Somatropin	Phase 2	Turner Syndrome
Once weekly subcutaneous injection of TransCon hGH	Phase 3	Growth Hormone Deficiency, Pediatric
TransCon IL-2 β/γ	Phase 2	Advanced Solid Tumor
Lonapegsomatropin	Phase 3	Growth Hormone Deficiency
Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections	Phase 2	Achondroplasia

Price & technical context

3-month

+17.1%

6-month

+26.9%

12-month

+55.2%

52-wk range

$163.32–$267.79

vs 50-day MA

+14.8%

vs 200-day MA

+21.8%

Realized vol

37.4%

Max drawdown

-22.1%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ASND (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 10 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.